en Oncology Oncology Original Research Original Research A retrospective study was done on 130 AML patients treated in Shariati and Imam Hospitals in Tehran from 1991 to 1997 to investigate the value of three post-remission methods of treatment. All patients who were in complete remission (CR) (Group I) had been treated with ARA-C (300 mg/m2/day continuous infusion for 5 days) and Daunorubicine (45 mg/m2/day for 3 days) as induction and early consolidation therapy. Forty patients were treated by additional similar chemotherapy as second consolidation and no further treatment was offered. Fifty patients (Group II) were treated by ARA-C (120 mg/m2 subcutaneously for 5 days), Etoposide (120 mg/m2 on day one), and Mitoxantrone (12 mg/m2 on day one) on each successive month as short-term miniconsolidation. Forty patients (Group III) were treated similarly to Group II until relapse for up to two years as long-term miniconsolidation. There was no difference in the three groups regarding mean age and other prognostic factors. Treatment related mortality and morbidity were also similar. Median duration of disease-free survival (DFS) was 36 (3.5-68 with 95% CI), 17 (12.5-21.5) and 19 (14.7-23.3) months respectively in these three groups. In a 14- month median observation there was no difference in DFS and overall survival (OS) among the three groups (p=0.7). We concluded that short- or long-term miniconsolidation chemotherapy compared to standard treatment does not improve DFS and OS in AML patients. Acute Myelogenous Leukemia, Consolidation, Maintenance Treatment. 61 66 http://mjiri.iums.ac.ir/browse.php?a_code=A-10-298-259&slc_lang=en&sid=1 P NASSERI 20031947532846004164 20031947532846004164 Yes From the Department of Hematology-Oncology, Tehran University of Medical Sciences, Tehran, I.R. Iran. A GHAVAMZADEH 20031947532846004165 20031947532846004165 No M KEYHANI ELAHI 20031947532846004166 20031947532846004166 No RA SHARIFIAN 20031947532846004167 20031947532846004167 No J NATEGHI 20031947532846004168 20031947532846004168 No K ALIMOGHADAM 20031947532846004169 20031947532846004169 No MR MORTAZAVIZADEH 20031947532846004170 20031947532846004170 No M ABASI 20031947532846004171 20031947532846004171 No MR ESHRAGHIAN 20031947532846004172 20031947532846004172 No